Atlas Venture announced the close of a $400 million Opportunity Fund III to support follow-on investments in its existing portfolio of biotech startups. The fund aims to provide additional capital to companies facing difficult financing environments, enabling progress toward clinical and commercial milestones. This marks the third such fund by Atlas, complementing its early-stage venture fund, and indicates sustained confidence in its seed-led venture creation model and the pipeline of biotechnology innovation.